CAR-T Meeting 2024 | Safety and efficacy of Actaly-cel™ in R/R pediatric B-ALL
Gaurav Narula, MD, Tata Memorial Center, Mumbai, India, presents encouraging results from a Phase I/Ib trial (CTRI/2023/03/050689) on actalycabtagene autoleucel (Actaly-cel™), a CAR-T product for pediatric relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). The trial demonstrated favorable safety outcomes, showcasing a minimal incidence of cytokine release syndrome (CRS) and neurotoxicity. Regarding efficacy, patients receiving a dose surpassing 3×10^-6/kg achieved an overall response rate (ORR) of 100%, with 88% achieving measurable residual disease (MRD) negativity. This interview took place at the EBMT-EHA 6th European CAR T-cell Meeting in Valencia, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Advisory Board: ImmunoACT.
